Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine

- Aged 12-13 months on the day of inclusion

- Born at full term of pregnancy (>37 weeks) with a birth weight ≥ 2.5 kg

- Informed consent form signed by the parent(s) or other legal representative

- Able to attend all scheduled visits and to comply with all trial procedures

- Subjects having received only one or no injection of vaccine against Measles

- Subjects anti-HAV seronegative according to the results obtained at the screening visit*

- Participation in another clinical trial in the 4 weeks preceding the (first) trial vaccination

- Planned participation in another clinical trial during the present trial period

- Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy

- Systemic hypersensitivity to any of the vaccines components or history of a life-threatening reaction to the trial vaccines or a vaccine containing the same substances

- Chronic illness at a stage that could interfere with trial conduct or completion

- Blood or blood-derived products received in the past 3 months

- Any vaccination in the 4 weeks preceding the first trial vaccination

- Vaccination planned in the 4 weeks following any trial vaccination

- History of hepatitis A, Mumps, Measles and/or Rubella infection (confirmed either clinically, serologically or microbiologically)

- Previous vaccination against hepatitis A with the trial vaccine or another vaccine

- Previous vaccination against Mumps, Measles and Rubella with a Mumps, Measles and Rubella trivalent combined vaccine

- Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination

- History of seizures

- Febrile illness (axillary temperature ≥37.4°C]) on the day of inclusion